PT2904009T - Compostos para o tratamento do bloqueio da remielinização em doenças associadas com a expressão da proteína do invólucro de herv-w - Google Patents

Compostos para o tratamento do bloqueio da remielinização em doenças associadas com a expressão da proteína do invólucro de herv-w

Info

Publication number: PT2904009T
Authority: PT; Portugal
Prior art keywords: remellinization; herv; shallow; compounds; treatment
Prior art date: 2012-10-02

Application number

PT13770926T

Other languages

English (en)

Inventor

Perron Hervé

Firouzi Reza

Küry Patrick

Faucard Raphaël

Madeira Alexandra

Joanou Julie

Original Assignee

Geneuro Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-10-02

Filing date

2013-10-01

Publication date

2019-02-19

2013-10-01 Application filed by Geneuro Sa filed Critical Geneuro Sa

2019-02-19 Publication of PT2904009T publication Critical patent/PT2904009T/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/112—Retroviridae (F), e.g. leukemia viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Emergency Medicine (AREA)
Microbiology (AREA)
Mycology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Psychiatry (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Oncology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

PT13770926T 2012-10-02 2013-10-01 Compostos para o tratamento do bloqueio da remielinização em doenças associadas com a expressão da proteína do invólucro de herv-w PT2904009T (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261708779P	2012-10-02	2012-10-02
US201261746792P	2012-12-28	2012-12-28

Publications (1)

Publication Number	Publication Date
PT2904009T true PT2904009T (pt)	2019-02-19

Family

ID=49274655

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT181983099T PT3447070T (pt)	2012-10-02	2013-10-01	Compostos para o tratamento do bloqueio da remielinização em doenças associadas com a expressão da proteína do invólucro de herv-w
PT13770926T PT2904009T (pt)	2012-10-02	2013-10-01	Compostos para o tratamento do bloqueio da remielinização em doenças associadas com a expressão da proteína do invólucro de herv-w

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PT181983099T PT3447070T (pt)	2012-10-02	2013-10-01	Compostos para o tratamento do bloqueio da remielinização em doenças associadas com a expressão da proteína do invólucro de herv-w

Country Status (31)

Country	Link
US (2)	US9840550B2 (pt)
EP (2)	EP3447070B9 (pt)
JP (2)	JP6379331B2 (pt)
KR (1)	KR102098033B1 (pt)
CN (2)	CN105709224B (pt)
AU (2)	AU2013326552B2 (pt)
BR (1)	BR112015007150A8 (pt)
CA (1)	CA2882781C (pt)
CY (2)	CY1121237T1 (pt)
DK (2)	DK2904009T3 (pt)
EA (2)	EA028245B1 (pt)
EC (1)	ECSP15014925A (pt)
ES (2)	ES2710748T3 (pt)
HR (2)	HRP20190274T1 (pt)
HU (2)	HUE054051T2 (pt)
IL (3)	IL237474A0 (pt)
IN (1)	IN2015DN02397A (pt)
LT (2)	LT3447070T (pt)
MX (2)	MX385003B (pt)
MY (1)	MY172209A (pt)
PL (2)	PL2904009T3 (pt)
PT (2)	PT3447070T (pt)
RS (2)	RS58320B1 (pt)
RU (1)	RU2636355C2 (pt)
SA (1)	SA515360207B1 (pt)
SG (1)	SG11201501274VA (pt)
SI (2)	SI2904009T1 (pt)
SM (1)	SMT201900087T1 (pt)
UA (1)	UA119032C2 (pt)
WO (1)	WO2014053489A1 (pt)
ZA (1)	ZA201501491B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2949342A1 (en) *	2014-05-28	2015-12-02	Geneuro SA	Antiretroviral drug targeting human endogenous retrovirus
EP3351265A1 (en) *	2017-01-20	2018-07-25	Geneuro SA	Anti-herv-k envelope antibody and uses thereof
WO2018159787A1 (ja)	2017-03-01	2018-09-07	国立大学法人北海道大学	疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法
WO2020045683A1 (ja) *	2018-09-01	2020-03-05	国立大学法人北海道大学	ストレス負荷が関与する疾患を予防及び／又は治療するための医薬
EP4025303A1 (en) *	2019-09-04	2022-07-13	Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)	Herv inhibitors for use in treating tauopathies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2753098B1 (fr) *	1996-09-06	1998-11-27	Sod Conseils Rech Applic	Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
EP1265989A2 (en) *	2000-03-21	2002-12-18	MS Research A/S	An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
RU2420537C2 (ru) *	2001-01-17	2011-06-10	Трабьон Фармасьютикалз Инк.	Слитые белки связывающий домен-иммуноглобулин
FR2865403B1 (fr) *	2004-01-23	2009-06-12	Biomerieux Sa	Composition pour le traitement d'une pathologie associee a la msrv/herv-w
US20090233888A1 (en) *	2005-03-23	2009-09-17	Usc Stevens, University Of Southern California	Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
US8410115B2 (en) *	2006-02-28	2013-04-02	Elan Pharmaceuticals, Inc.	Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
ES2599227T3 (es) *	2007-02-08	2017-01-31	Biogen Ma Inc.	Neuroprotección en enfermedades desmielinizantes
WO2009062926A1 (en) *	2007-11-12	2009-05-22	Ares Trading S.A.	Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis
PL3211005T3 (pl) *	2008-07-08	2021-11-29	Geneuro Sa	Terapeutyczne zastosowanie specyficznego liganda w chorobach związanych z MSRV
WO2010045265A1 (en) *	2008-10-13	2010-04-22	Biovista, Inc.	Compositions and methods for treating multiple sclerosis
WO2010148323A2 (en) *	2009-06-18	2010-12-23	Whittemore Peterson Institute For Neuro-Immune Disease	Diagnosis and treatment of diseases or disorders associated with xenotropic murine leukemia virus
EP2982371A1 (en) *	2010-02-12	2016-02-10	Biogen MA Inc.	Dimethyl fumarate with glatiramer acetate or interferon-beta for treating multiple sclerosis

2013
- 2013-01-10 UA UAA201504292A patent/UA119032C2/uk unknown
- 2013-10-01 PT PT181983099T patent/PT3447070T/pt unknown
- 2013-10-01 RS RS20190185A patent/RS58320B1/sr unknown
- 2013-10-01 WO PCT/EP2013/070452 patent/WO2014053489A1/en not_active Ceased
- 2013-10-01 CA CA2882781A patent/CA2882781C/en active Active
- 2013-10-01 ES ES13770926T patent/ES2710748T3/es active Active
- 2013-10-01 MY MYPI2015700643A patent/MY172209A/en unknown
- 2013-10-01 EA EA201590678A patent/EA028245B1/ru unknown
- 2013-10-01 JP JP2015533633A patent/JP6379331B2/ja active Active
- 2013-10-01 EA EA201791525A patent/EA037253B1/ru unknown
- 2013-10-01 SM SM20190087T patent/SMT201900087T1/it unknown
- 2013-10-01 SI SI201331348T patent/SI2904009T1/sl unknown
- 2013-10-01 ES ES18198309T patent/ES2878248T3/es active Active
- 2013-10-01 EP EP18198309.9A patent/EP3447070B9/en active Active
- 2013-10-01 KR KR1020157011152A patent/KR102098033B1/ko not_active Expired - Fee Related
- 2013-10-01 IN IN2397DEN2015 patent/IN2015DN02397A/en unknown
- 2013-10-01 MX MX2019008916A patent/MX385003B/es unknown
- 2013-10-01 RS RS20210555A patent/RS61794B1/sr unknown
- 2013-10-01 LT LTEP18198309.9T patent/LT3447070T/lt unknown
- 2013-10-01 US US14/429,199 patent/US9840550B2/en not_active Expired - Fee Related
- 2013-10-01 PT PT13770926T patent/PT2904009T/pt unknown
- 2013-10-01 AU AU2013326552A patent/AU2013326552B2/en not_active Ceased
- 2013-10-01 HR HRP20190274TT patent/HRP20190274T1/hr unknown
- 2013-10-01 PL PL13770926T patent/PL2904009T3/pl unknown
- 2013-10-01 LT LTEP13770926.7T patent/LT2904009T/lt unknown
- 2013-10-01 CN CN201610152679.5A patent/CN105709224B/zh not_active Expired - Fee Related
- 2013-10-01 PL PL18198309T patent/PL3447070T3/pl unknown
- 2013-10-01 BR BR112015007150A patent/BR112015007150A8/pt not_active Application Discontinuation
- 2013-10-01 MX MX2015003572A patent/MX366846B/es active IP Right Grant
- 2013-10-01 DK DK13770926.7T patent/DK2904009T3/en active
- 2013-10-01 HU HUE18198309A patent/HUE054051T2/hu unknown
- 2013-10-01 SG SG11201501274VA patent/SG11201501274VA/en unknown
- 2013-10-01 HU HUE13770926A patent/HUE043419T2/hu unknown
- 2013-10-01 CN CN201380051713.4A patent/CN104684927B/zh not_active Expired - Fee Related
- 2013-10-01 EP EP13770926.7A patent/EP2904009B1/en active Active
- 2013-10-01 RU RU2015116149A patent/RU2636355C2/ru active
- 2013-10-01 DK DK18198309.9T patent/DK3447070T3/da active
- 2013-10-01 SI SI201331879T patent/SI3447070T1/sl unknown
2015
- 2015-02-26 IL IL237474A patent/IL237474A0/en unknown
- 2015-03-04 ZA ZA2015/01491A patent/ZA201501491B/en unknown
- 2015-03-30 SA SA515360207A patent/SA515360207B1/ar unknown
- 2015-04-17 EC ECIEPI201514925A patent/ECSP15014925A/es unknown
2017
- 2017-11-07 JP JP2017214696A patent/JP6538138B2/ja not_active Expired - Fee Related
- 2017-11-14 US US15/812,745 patent/US10752675B2/en active Active
2018
- 2018-08-17 AU AU2018217328A patent/AU2018217328B2/en not_active Ceased
2019
- 2019-01-21 IL IL264382A patent/IL264382B/en active IP Right Grant
- 2019-02-07 CY CY20191100169T patent/CY1121237T1/el unknown
2020
- 2020-04-19 IL IL274047A patent/IL274047B/en active IP Right Grant
2021
- 2021-05-11 CY CY20211100400T patent/CY1124378T1/el unknown
- 2021-05-14 HR HRP20210779TT patent/HRP20210779T1/hr unknown

Also Published As

Publication number	Publication date
SG11201501274VA (en)	2015-05-28
EP2904009A1 (en)	2015-08-12
PL2904009T3 (pl)	2019-06-28
LT2904009T (lt)	2019-03-12
MX2015003572A (es)	2015-08-20
MY172209A (en)	2019-11-15
AU2018217328B2 (en)	2019-09-19
EA201590678A1 (ru)	2015-07-30
PL3447070T3 (pl)	2021-09-06
PT3447070T (pt)	2021-05-19
IL264382A (en)	2019-02-28
IL264382B (en)	2020-05-31
JP2018065814A (ja)	2018-04-26
CN105709224A (zh)	2016-06-29
RU2015116149A (ru)	2016-11-27
AU2018217328A1 (en)	2018-09-06
RS58320B1 (sr)	2019-03-29
KR20150064147A (ko)	2015-06-10
UA119032C2 (uk)	2019-04-25
DK3447070T3 (da)	2021-05-10
JP2016500651A (ja)	2016-01-14
EA037253B1 (ru)	2021-02-26
MX366846B (es)	2019-07-26
IL274047A (en)	2020-06-30
SMT201900087T1 (it)	2019-02-28
JP6538138B2 (ja)	2019-07-03
RS61794B1 (sr)	2021-06-30
HRP20190274T1 (hr)	2019-04-05
BR112015007150A2 (pt)	2017-07-04
JP6379331B2 (ja)	2018-08-29
EP2904009B1 (en)	2018-11-21
LT3447070T (lt)	2021-06-10
DK2904009T3 (en)	2019-03-11
CY1121237T1 (el)	2020-05-29
ES2710748T3 (es)	2019-04-26
CA2882781C (en)	2021-06-15
US9840550B2 (en)	2017-12-12
HUE043419T2 (hu)	2019-08-28
IN2015DN02397A (pt)	2015-09-04
CN104684927A (zh)	2015-06-03
EA201791525A2 (ru)	2018-07-31
CY1124378T1 (el)	2022-07-22
HK1221399A1 (zh)	2017-06-02
EA028245B1 (ru)	2017-10-31
WO2014053489A1 (en)	2014-04-10
EP3447070A1 (en)	2019-02-27
AU2013326552A1 (en)	2015-03-05
HUE054051T2 (hu)	2021-08-30
EP3447070B1 (en)	2021-02-24
US20150218256A1 (en)	2015-08-06
IL274047B (en)	2020-11-30
CN104684927B (zh)	2018-06-19
SA515360207B1 (ar)	2018-09-18
IL237474A0 (en)	2015-04-30
HRP20210779T1 (hr)	2021-09-17
ES2878248T3 (es)	2021-11-18
ZA201501491B (en)	2016-01-27
MX2019008916A (es)	2019-11-11
KR102098033B1 (ko)	2020-04-08
MX385003B (es)	2025-03-14
EA201791525A3 (ru)	2018-12-28
ECSP15014925A (es)	2017-07-31
SI3447070T1 (sl)	2021-08-31
RU2636355C2 (ru)	2017-11-22
US10752675B2 (en)	2020-08-25
AU2013326552B2 (en)	2018-05-24
BR112015007150A8 (pt)	2018-02-06
US20180066040A1 (en)	2018-03-08
CA2882781A1 (en)	2014-04-10
SI2904009T1 (sl)	2019-04-30
CN105709224B (zh)	2020-06-05
EP3447070B9 (en)	2021-08-11

Publication	Publication Date	Title
LTPA2020510I1 (lt)	2020-07-10	Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui
IL235512B (en)	2018-06-28	Phenylbenzamide derivatives for use in treating diseases mediated by aquaporin
EP2906208A4 (en)	2016-06-08	THERAPEUTIC TREATMENT
EP2858557A4 (en)	2016-03-09	IMPROVED REANIMATION
EP2814427A4 (en)	2015-10-07	RIGHT-VENTRICULAR PAPILLAR APPROACH
BR112014031806A2 (pt)	2017-08-29	método para tratamento de câncer positivo para gd2
PT2919796T (pt)	2021-06-02	Utilização de akkermansia para o tratamento de distúrbios metabólicos
ME02914B (me)	2018-10-20	Novi terapeutski agensi
HRP20180939T1 (hr)	2018-12-14	Kombinirana terapija za liječenje multiple skleroze
PT2729151T (pt)	2021-05-25	Composição farmacêutica, métodos de tratamento e suas utilizações
PL2717692T3 (pl)	2020-06-15	Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych
HUE051632T2 (hu)	2021-03-29	Betegségek kezelésére szolgáló készítmények és eljárások
PT2872497T (pt)	2017-04-24	Derivados de cromanilo para o tratamento de doenças mitocondriais
HUE068364T2 (hu)	2024-12-28	Faktor 1 fehérje betegségek kézélésében vagy megelõzésében váló alkalmazásra
EP2865378A4 (en)	2016-03-02	SKIN PATCH
IL238481B (en)	2018-11-29	Synthetic lethality and the treatment of cancer
PT2750709T (pt)	2018-11-22	Tratamento da caquexia
LTPA2020511I1 (lt)	2020-07-27	Ciklezonidas, skirtas arklių kvėpavimo takų ligų gydymui
HRP20190050T1 (hr)	2019-03-08	Farmaceutski pripravci za kombinacijsku terapiju
HUE051295T2 (hu)	2021-03-01	Módosított fibroblaszt növekedési faktorok-1 szembetegségek kezelésére
BR112014029487A2 (pt)	2017-06-27	método para o tratamento cosmético
EP2789306A4 (en)	2015-11-04	TREATMENT SYSTEM
PT2904009T (pt)	2019-02-19	Compostos para o tratamento do bloqueio da remielinização em doenças associadas com a expressão da proteína do invólucro de herv-w
BR302013000073S1 (pt)	2014-11-18	Configuração aplicada em artigo médico
ITRM20120530A1 (it)	2014-05-01	Compounds for use in the treatment of parasitic diseases